
Roche Itovebi gets European Commission nod in fight against advanced breast cancer
Basel: Roche has received approval from the European Commission for Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal …